Dr. Ioannis Tarnanas pioneered virtual and augmented reality environments for everyday function monitoring. In 2005, he became involved in the world’s first digital biomarker project, Novartis AG’s smart exelon patch, which was approved by the FDA in 2013. He recently created an accurate predictive tool based on cognitive and non-cognitive digital biomarkers of early onset dementia. Dr. Tarnanas currently serves as the Principal Investigator of the Alzheimer’s Drug Discovery Foundation (ADDF) project entitled “Digitally-enhanced personalized medicine: accurate selection of subjective cognitive decline and measuring progression of mild cognitive impairment” (reference #DADB-201906-2018897); the project addresses the validation of Altoida’s Software as a Medical Device (SaMD) for the accurate selection of subjective cognitive decline and measuring progression of mild cognitive impairment in individuals at risk of AD/ADRD. In addition, Dr. Tarnanas has been a Principal Investigator for the Research & Development and validation studies of Altoida’s Software as a Medical Device (SaMD), totaling $4.3 million in public funding & $24 million in private funding. He is the founder and Chief Scientific Officer for Altoida and has been responsible for interactions with the FDA, which has awarded the breakthrough designation to Altoida’s predictive SaMD system. Finally, Dr. Tarnanas is part of the expert evaluators for the European Institute for Innovation and Technology, Health sector (EIT Health) for Brain & Mental Health and Digital Biomarkers. Dr. Tarnanas received his PhD in Neuroscience from Aristotle University of Thessaloniki, Greece.